TBR-760 halts tumor growth in mice
CAMBRIDGE, Mass.—New data from Tiburio Therapeutics Inc. was published in the Journal of the Endocrine Society recently demonstrating that TBR-760 was capable of completely halting the growth of non-functioning pituitary adenoma (NFPA) in a mouse model. Twenty percent of the mice treated with TBR-760 saw significant shrinkage of their tumors. TBR-760, Tiburio’s lead compound, is a dopamine somatostatin chimeric compound being advanced as a potential treatment for NFPAs in hopes of reducing or eliminating the need for radiation and surgery.
Dr. Michael Culler, scientific founder and chairman of the scientific advisory board, noted, “Ultimately, these results support the development of TBR-760 as a medical therapy to either prevent or arrest the growth of NFPAs, and with the potential to induce NFPA shrinkage. NFPAs are the only type of pituitary adenoma without an approved medical therapy.”